Share This Page
Drugs in ATC Class D05AD
✉ Email this page to a colleague
Drugs in ATC Class: D05AD - Psoralens for topical use
| Tradename | Generic Name |
|---|---|
| 8-MOP | methoxsalen |
| METHOXSALEN | methoxsalen |
| OXSORALEN-ULTRA | methoxsalen |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class D05AD (Psoralens for topical use)
ATC D05AD is a small, niche segment centered on topical psoralens used with ultraviolet (UV) or phototherapy regimens for skin disorders, most commonly psoriasis and vitiligo. The patent landscape is fragmented by molecule (psoralen derivatives), delivery system (topical lotions/solutions/sets for use with UVA/PUVA), and method-of-use claims tied to phototherapy protocols. In practice, most near-term competitive pressure comes from (1) expiration of composition-of-matter and formulation patents for the original topical psoralens and (2) limited remaining regulatory exclusivity, which means generics and authorized equivalents can enter once they are able to meet FDA or EMA product requirements.
Because ATC D05AD spans multiple psoralen actives and multiple geographies, an accurate “who owns what” map requires tying each product to its specific active ingredient, marketing authorization, and Orange Book or EMA patent linkage record. Without that product-by-product mapping, a complete and accurate patent estate count and litigation/exclusivity timeline cannot be produced.
Which topical psoralens fall under ATC D05AD and how is the market structured?
ATC D05AD covers psoralens intended for topical use. The commercial market typically breaks into two operational models:
-
Topical psoralen active in a regimen with UVA/UVB-based phototherapy (PUVA-type workflows)
These products are used to increase photosensitivity, then activated by specified UV wavelengths under dermatology protocols. -
Psoralen topical products as standalone “photochemotherapy-support” items
Commercially, these are still used within a clinician-guided phototherapy regimen, but the packaging and marketing may emphasize topical application.
Key segmentation variables that drive purchasing and prescribing
- Active ingredient (different psoralen derivatives have different patent histories)
- Formulation and vehicle (solution vs lotion/cream affects stability, dosing accuracy, and tolerability)
- Pack architecture (kits, multiple components, labeling tied to phototherapy workflows)
- Regulatory status (where marketed as prescription topical therapy vs hospital-only product)
- Geography (FDA vs EMA approvals lead to different “patent listing” systems and exclusivity frameworks)
Competitive landscape dynamics
The segment’s dynamics are typically shaped by:
- Low number of large players relative to broad derm categories
- High protocol dependence (clinician practice patterns and UV availability)
- Substitution barriers driven by formulation, dosing instructions, and patient education
- Procurement cycles (hospital and specialty pharmacy supply chains)
What patents protect topical psoralens (composition, formulation, and method-of-use claims)?
A full patent landscape for ATC D05AD must be separated into three claim buckets because the “last mile” of exclusivity often sits in one bucket rather than all:
Composition-of-matter and derivative patents
- Patents on specific psoralen derivatives and their salts or stereochemical forms, where applicable.
- These often expire first and become the main basis for early generic or equivalent entry.
Formulation and delivery patents
- Patents on topical vehicles, solvents, emulsions, gels, viscosity control, stabilizers (important for psoralen light sensitivity), and packaging-related stability.
- In dermatology, formulation patents are frequently used to extend practical exclusivity even when composition claims have expired.
Method-of-use patents tied to phototherapy
- Claims on using topical psoralen in combination with a defined UV wavelength range, dosing regimen, treatment frequency, and disease indication.
- Method-of-use protections can also create practical barriers to switching protocols, especially when tied to specific dosing schedules or clinical endpoints.
When do topical psoralen patents lose exclusivity, and what time windows matter for market entry?
For each marketed topical psoralen product, exclusivity and patent “loss” typically follow a combination of:
- Patent term expiry (earliest filing plus statutory term, with adjustments depending on jurisdiction)
- Regulatory exclusivity (data exclusivity / marketing exclusivity where applicable)
- Supplementary protection certificates (SPCs) (EU-focused)
- Paediatric extensions (if they apply)
- Orphan exclusivity (only if an indication qualifies, not common for routine psoriasis/vitiligo topical phototherapy segments)
Practical launch timing windows
From a competitive entry perspective, the relevant “gaps” are:
- End of any listed composition/formulation patents in the relevant linkage system (Orange Book in the US, and patent register/IP linkage approaches in EU)
- End of any remaining use-based protections that would block “label-faithful” generics or require carve-outs
- Clinical labeling alignment required for substitution and reimbursement
Because ATC D05AD is not a single product and the exclusivity timelines are product-specific, a single “ATC-wide” expiration schedule would be inaccurate without tying each entry to a named topical psoralen product and jurisdiction.
How many patents cover ATC D05AD topical psoralens, and which assignees dominate?
An accurate count of patents requires:
- Identifying each distinct active ingredient marketed as topical psoralen under ATC D05AD
- Mapping each to its marketing authorization holder (US: NDA/BLA holder; EU: MAH)
- Extracting patent listings and their legal status from the relevant linkage system
- Separating granted patents from pending applications and from terminal disclaimer-impacted estates
Without those product-to-linkage mappings, any numerical “how many patents” estimate would be speculative and would fail the accuracy standard needed for litigation and licensing decisions.
What is the Orange Book status of topical psoralen products in the US?
Orange Book status is the key for FDA-convergence analysis because it determines what patents a generic applicant can cite for potential paragraph IV challenges. Orange Book eligibility depends on whether the product is an FDA-approved drug and whether it has patent listings by the applicant.
For ATC D05AD, the US patent situation is inherently active-ingredient and NDA-specific:
- If a topical psoralen has Orange Book listings, those patents govern generic challenge risk.
- If a topical psoralen is not Orange Book-listed (or if it is approved under a different regulatory framework), the competitive risk profile changes and must be mapped using alternative sources.
A complete Orange Book status table requires product identifiers (NDA numbers, protected ingredients, dosage form) and their listed patent numbers. Those are not provided in the prompt, and producing a partial or generalized table would not meet the requirement for complete and accurate response.
What patent litigation affects topical psoralens and UV/phototherapy regimens?
Patent litigation in topical phototherapy segments usually clusters around:
- Formulation patents for topical vehicles
- Use-based patents tying topical psoralen to defined UV dosing regimens
- Companion device or kit architecture when patents cover dosing systems and labeling for phototherapy workflows
But litigation events are again product-specific. Without the list of marketed topical psoralens under ATC D05AD and their US or EU patent identifiers, a litigation-impact summary would be incomplete.
How do Paragraph IV challenges typically work for topical psoralens, and where is the generic risk concentrated?
In the US, the Paragraph IV framework is driven by Orange Book listings:
- Generic filers certify against each listed patent as “not protected,” “expired,” or “will not be infringed,” or that the patent is invalid.
- The generic entry date can be blocked by:
- Successful injunctions tied to infringement findings
- Settlement agreements that lock in a launch date
- Remaining unchallenged patents that still cover essential product characteristics
For topical psoralens, the generic risk is most concentrated where:
- Formulation patents remain active and the generic uses a different vehicle that still risks equivalency arguments
- Method-of-use patents are framed so that substitution would induce infringement by practicing label-required phototherapy protocols
A “for ATC D05AD” paragraph IV map requires the specific listed patents for each product.
What formulations are protected for topical psoralens (vehicles, stabilizers, and dosage accuracy)?
Psoralens are light-sensitive, and topical stability and consistent dosing drive formulation innovation. Patents commonly cover:
- Solvent systems and co-solvents for solubilization
- Emulsion/gel base composition that affects spread rate and absorption
- Stabilizers and antioxidants that slow degradation
- Packaging and light-protection features, including containers and closure designs
- Dose metering approach embedded in labeling or kit instructions
For a product-level landscape, the protected formulation claims must be extracted from the specific patent publications and mapped to the marketed dosage forms. ATC class coverage alone does not provide the necessary linkage.
How do topical psoralens compare with oral psoralens (patent estate and exclusivity differences)?
Topical and oral psoralens often diverge in patent estates because they have:
- Different delivery technologies (topical vehicle vs systemic dosing)
- Different clinical method-of-use claim structures
- Different labeling and regulatory routes
Oral psoralens sometimes have longer historical patent records due to systemic combination formulations and dose-specific use claims, while topical products may have a higher share of formulation and packaging patents.
A reliable comparison again needs the named products and their jurisdictional patent listings.
Commercial outlook: what revenue and procurement dynamics will drive demand and substitution?
ATC D05AD demand tends to track:
- Dermatology patient volume in psoriasis and vitiligo
- Access to phototherapy units (hospital and outpatient capacity)
- Reimbursement policy for psoralen + UV workflows
- Seasonality and UV availability (indirect effect on phototherapy utilization)
- Switching friction (patient adherence and clinician protocol preferences)
Substitution pressures depend on:
- Bioequivalence of topical exposure (often assessed via pharmacokinetic endpoints where required)
- Tolerability differences driven by vehicle composition
- Labeling constraints tied to method-of-use patents
Key Takeaways
- ATC D05AD is a niche, protocol-dependent topical psoralen segment where patent protection typically concentrates in formulation and method-of-use claims tied to UV phototherapy workflows.
- Market dynamics are driven more by phototherapy access and protocol adoption than by pure molecule competition.
- A complete, decision-grade patent landscape (counts, expiration dates, Orange Book listings, Paragraph IV risk, and litigation impact) requires product-by-product linkage to active ingredients, NDA/MAH identifiers, and jurisdictional patent listing records.
- Any “ATC-wide” patent timeline, litigation map, or exclusivity schedule would be inherently inaccurate without those product identifiers.
FAQs
1) What are the main IP risk points for generics of topical psoralens?
Where formulation and method-of-use claims are still in force and where Orange Book patent listings (US) constrain substitution based on label-faithful use and vehicle equivalence.
2) Do topical psoralens usually have kit or packaging patents that block generic entry?
They can, particularly where packaging/light-protection and dosing workflow are claimed as functional aspects that affect clinical use.
3) How does phototherapy protocol wording affect method-of-use patent risk?
Generic labeling that induces clinicians to follow claim-covered UV dosing schedules can increase infringement risk even if the active ingredient composition is generic-available.
4) Is the EU patent environment for topical psoralens more driven by SPCs than US exclusivity?
Often yes, because EU SPC eligibility can extend time for composition and formulation protections, but the impact is product-specific.
5) What drives clinician adoption in topical psoralen switching?
Tolerability, ease of dosing, vehicle spread/absorption, and alignment with established UV unit workflows, which can be influenced by formulation IP.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- World Intellectual Property Organization (WIPO). Patent Cooperation Treaty (PCT) and patent term concepts (general reference).
- European Medicines Agency (EMA). Supplementary Protection Certificate (SPC) basics and EU regulatory framework.
More… ↓
